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Introduction
The ability to edit DNA sequences is critical to a wide range 
of basic and applied sciences. Detailed comparison studies 
of genome engineering strategies are imperative to evaluate 
the characteristics and effects of these technologies. Zinc 
finger nucleases (ZFNs) and transcriptional activator-like 
effector nucleases (TALENs) have been firmly established 
as efficient gene-editing technologies over the past decade. 
In clinical trials for human immunodeficiency virus infec-
tion, ZFN-mediated disruption of the C-C chemokine recep-
tor 5 locus in T lymphocytes has produced salutary effects, 
and ZFNs are currently being evaluated in clinical trials for 
treatment of glioblastoma and hemoglobinopathies.1,2 The 
recent development of clustered regularly interspaced short 
palindromic repeat (CRISPR)/Cas9 has enabled widespread 
application of genome engineering and virtually constitutes 
a paradigm shift in the research field due to the simplicity of 
designing a guideRNA (gRNA) to any target. Nevertheless, 
although high site-specific nuclease activity of the CRISPR/
Cas9 has been demonstrated in cell lines, there has, with 
the exception of two recent publications(3, 4), been to date a 
paucity of studies examining the efficiency of CRISPR/Cas9 
in primary human hematopoietic stem and progenitor cells 
(HSPCs).
Inherent nuclease properties determine their efficacy to 
facilitate permanent site-specific genome engineering by 
induction of DNA double-strand breaks (DSBs) that result 
in insertions and deletions (indels) through the error-prone 
nonhomologous end-joining (NHEJ) DNA repair pathway. 
ZFNs and TALENs rely on protein-based systems with des-
ignable DNA binding specificities. The ZFNs consist of an 
endonucleolytic domain, FokI, that is tethered to engineered 
Cys2His2 zinc-finger DNA-binding polypeptides5,6; two ZFNs 
are required to bind opposite DNA strands at a set distance 
for the FokI domains to dimerize and create a DSB. TALENs 
also depend on two FokI nuclease domains to dimerize in 
order to induce site-specific DNA cleavage but consist of 
assembled TAL effector DNA-binding motifs, each motif con-
sisting of tandem repeats that bind to a single base pair.7,8 
The Type II RNA-guided CRISPR/Cas9 consists of a short 
gRNA sequence (20 variable bases target sequence that 
encodes crRNA) that targets the Cas9 endonuclease through 
Watson–Crick RNA–DNA base pairing to cleave the DNA.9,10
Efficient non-cytotoxic delivery is a prerequisite to 
achieve maximum genome engineering potential of 
Received 17 April 2016; accepted 18 April 2016; published online 16 August 2016. doi:10.1038/mtna.2016.52
2162-2531
e351
Molecular Therapy—Nucleic Acids
10.1038/mtna.2016.52
Original Article
16August2016
5
17April2016
18April2016
2016
Official journal of the American Society of Gene & Cell Therapy
A Comparison Study of Targeted Endonucleases
Bjurström et al.
We examined the efficiency, specificity, and mutational signatures of zinc finger nucleases (ZFNs), transcriptional activator-
like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 systems 
designed to target the gene encoding the transcriptional repressor BCL11A, in human K562 cells and human CD34+ 
progenitor cells. ZFNs and TALENs were delivered as in vitro transcribed mRNA through electroporation; CRISPR/Cas9 
was codelivered by Cas9 mRNA with plasmid-encoded guideRNA (gRNA) (pU6.g1) or in vitro transcribed gRNA (gR.1). 
Analyses of efficacy revealed that for these specific reagents and the delivery methods used, the ZFNs gave rise to more 
allelic disruption in the targeted locus compared to the TALENs and CRISPR/Cas9, which was associated with increased 
levels of fetal hemoglobin in erythroid cells produced in vitro from nuclease-treated CD34+ cells. Genome-wide analysis 
to evaluate the specificity of the nucleases revealed high specificity of this specific ZFN to the target site, while specific 
TALENs and CRISPRs evaluated showed off-target cleavage activity. ZFN gene-edited CD34+ cells had the capacity to 
engraft in NOD-PrkdcSCID-IL2Rγnull mice, while retaining multi-lineage potential, in contrast to TALEN gene-edited CD34+ cells. 
CRISPR engraftment levels mirrored the increased relative plasmid-mediated toxicity of pU6.g1/Cas9 in hematopoietic stem/
progenitor cells (HSPCs), highlighting the value for the further improvements of CRISPR/Cas9 delivery in primary human 
HSPCs.
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nucleases, especially in delicate primary cells that cannot 
be effectively expanded ex vivo, such as HSPCs. Introduc-
tion of DNA to cells is associated with higher cytotoxicity 
compared to in vitro transcribed mRNA and introduced 
DNA might potentially undergo integration into the host 
genome.3,11–13 Conversely, RNA instability is challenging for 
the process of delivery, since RNA can undergo rapid intra-
cellular degradation.
The zinc-finger transcriptional factor BCL11A has been 
shown to silence embryonic and fetal globin genes in both 
mouse models and human cells during development and 
thus directly regulates fetal hemoglobin (HbF) switch-
ing.14–19 BCL11A silences HbF by associating with other 
known γ-globin transcriptional repressors and binding to the 
locus control region as well as other intergenic sites, which 
prevents the interaction between the locus control region 
and the HbF globin gene required for fetal globin expres-
sion.17,20–22 Individuals with incomplete hemoglobin switching 
and elevated HbF levels in adult life (hereditary persistence 
of HbF) exhibit milder symptomatology of sickle cell disease 
and β-thalassemia. Genome-wide association studies have 
revealed that variations in HbF levels are frequently caused 
by common polymorphisms in the BCL11A gene and the 
β-globin cluster.15,18,19,23 Knockdown of the BCL11A gene 
using precise artificially engineered nucleases that enable 
permanent site-specific genome engineering through the 
NHEJ DNA repair pathway is an attractive strategy to reac-
tivate HbF and restore functional erythrocytes. In this study, 
one ZFN pair, two TALEN pairs, and four CRISPR gRNAs, 
all designed to target exon 2 of the transcriptional repres-
sor of HbF—the BCL11A gene, were evaluated for efficacy, 
specificity, and toxicity in human cell lines and primary CD34+ 
cells. We compared the frequencies of indels induced in the 
BCL11A locus for the three systems in CD34+ cells, and func-
tional reactivation of HbF by high-performance liquid chroma-
tography (HPLC) after in vitro erythroid differentiation. The 
nuclease specificity was analyzed by investigating predicted 
off-target events in addition to a genome-wide screen to iden-
tify DSBs. Nuclease-treated CD34+ cells were tested in vivo 
by intravenous transplantation into immune-deficient NOD-
PrkdcSCID-IL2Rγnull (NSG) mice. This study demonstrates that 
component delivery optimization is still required for CRISPR/
Cas9 to achieve high genome editing efficiency in CD34+ 
cells.
Results
Delivery of plasmid and mRNA transcripts of the 
nucleases results in different toxicity responses and 
genome editing efficiencies
One ZFN pair, two TALENs, and four CRISPR/Cas9 gRNAs 
were designed to target exon 2 of the human BCL11A locus 
to induce HbF expression (Figure 1a, Table 1). To con-
firm functionality, the seven nucleases were initially evalu-
ated for gene disruption efficiencies of the BCL11A locus 
after electroporation of the nucleases into the K562 human 
hematopoietic cell line (Figure 1b). The ZFNs were deliv-
ered as in vitro transcribed mRNA (2 μg) transcripts, and 
the TALENs (2 μg) and CRISPR/Cas9 (4 μg) were delivered 
as expression plasmids. Administration of all nucleases 
resulted in high levels of cleavage at the BCL11A locus, as 
determined by the Surveyor nuclease assay (Figure 1b).
Initially, we assessed the efficiency and toxicity of electro-
poration of a GFP expression plasmid versus in vitro tran-
scribed green fluorescent protein (GFP) mRNA into CD34+ 
cells, determined by flow cytometry (GFP fluorescence and 
7-AAD uptake)  (Figure 1c). The cytotoxicity of the GFP plas-
mid was higher (and concentration dependent) compared to 
the GFP mRNA. Furthermore, expression from the in vitro 
transcribed mRNA was more efficient than expression from 
the plasmid. The TALENs and the Cas9 were cloned into a 
pGEM plasmid and thereafter in vitro transcribed to mRNA; 
gRNA + scaffold sequences were transcribed to RNA (gR.1) 
or delivered as a plasmid (pU6.g1) (Table 1). All nucleases 
were able to induce cleavage of the target locus in CD34+ 
cells with differing levels of efficiency. The ZFNs induced 
the highest percentage indels at 27%, the TALENs reached 
12% indels, and the gR.1/Cas9 induced only 4% indels 
(Figure 1d).
CRISPR/Cas9-mediated genome editing in CD34+ cells
Electroporation of the CRISPR/Cas9 plasmid (pX330.g1) 
that expresses both the gRNA (from a U6 promoter) and the 
Cas9 mRNA (from a CBh promoter) was examined at the 
concentrations 1, 2, 5, and 10 μg and compared to codeliv-
ery of gRNA expression plasmid (pU6.g1) and Cas9 mRNA. 
Electroporation of the pX330.g1 plasmid did not result in any 
cleavage at any of the concentrations tested in bulk CD34+ 
cells (Figure 2a), which is in concordance with previous 
results showing that this delivery method may require selec-
tion of the nuclease-treated CD34+ cells to detect activity.4 
However, codelivery by electroporation of the U6-driven 
gRNA expression plasmid (pU6.g1) and in vitro transcribed 
Cas9 mRNA resulted in 10–13% cleavage of the target locus 
when delivered at the concentrations: pU6.g1(5 μg): Cas9 
(5 μg) and pU6.g1(10 μg): Cas9 (10 μg) (Figure 2a). The 
cytotoxicity induced in CD34+ cells after delivery of plasmid 
alone (pX330) was assessed by flow cytometry after 1 and 
5 days (Supplementary Figure S1a). Electroporation of 
pX330.g1 or pU6.g1/Cas9 induced a similar percentage of 
cell death (Supplementary Figures S1a and S3c). Further-
more, electroporation of the in vitro transcribed gR.1 with 
Cas9 mRNA resulted only in 4–6% cleavage of the target 
locus, delivered at the concentrations: gR.1(5 μg): Cas9(5 
μg) and gR.1(10 μg): Cas9(10 μg) to CD34+ cells (Figure 2a). 
On the other hand, the toxicity associated with CRISPR/
Cas9 delivered as RNA was much lower (17–35% cell death) 
compared to the pX330 and pU6.g1/Cas9 (Supplementary 
 Figure S3b). Despite the higher toxicity from the pU6.g1/
Cas9 compared to gR.1/Cas9, combinatorial delivery of plas-
mid and mRNA was the most effective mode of delivery for 
CD34+ cells for disrupting the BCL11A locus.
In an attempt to increase the cleavage efficiencies further, 
we increased the number of gRNA expression cassettes in 
the plasmid, delivered with the Cas9 mRNA. Because trans-
fection of multiple plasmids can increase cytotoxicity and 
lower targeting efficiency, we instead produced four additional 
gRNA expression plasmids containing two or three copies 
of the same gRNA targeting the BCL11A sequence (pU6.
g2.2, pU6.g2.2.2) and two or three gRNA targeting different 
www.moleculartherapy.org/mtna
A Comparison Study of Targeted Endonucleases
Bjurström et al.
3
BCL11A sequences (pU6.g1.2, pU6.g1.2.3). While the cyto-
toxicity was comparable to the gRNA plasmid expressing one 
single gRNA (Supplementary Figure S1b,c), none of the 
multiplexed gRNA plasmids resulted in significant increased 
cleavage efficiency over the plasmid with the single gRNA 
(Figure 2b,c and Supplementary Figure S2a–c).
ZFN-mediated cleavage results in higher levels of 
allelic disruption in CD34+ cells compared to the other 
nucleases
After demonstrating successful cleavage at the targeted 
BCL11A locus in CD34+ cells, we titrated the ZFNs (Z1), 
TALENs (T1), and the two forms of CRISPR/Cas9 (gR.1/
Cas9 and pU6.g1/Cas9) to determine the optimal concentra-
tion resulting in the highest cleavage efficiency for each of 
the nucleases. At a concentration of 5 μg/arm, the ZFNs and 
TALENs produced ~25% and 15% cleavage, respectively 
(Figure 3a), and resulted in average acute cytotoxicity levels 
of 47% (range 40–60%) (ZFNs) and 38% (range 35–40%) 
(TALENs) (Supplementary Figure S3a).
Delivery of the gR.1/Cas9 and pU6.g1/Cas9 resulted in 
an average of 5% and 12% cleavage at the targeted locus 
in CD34+ cells when delivered at the concentrations of 5 μg 
gRNA and 5 μg Cas9 mRNA (Figure 3b,c). The cytotoxicity 
Figure 1  ZFNs, TALENs, and CRISPR/Cas9 nucleases targeting the human BCL11A gene delivered to human hematopoietic cells via 
plasmids and RNA. (a) Schematic of engineered nucleases targeting the BCL11A gene. Top: the human BCL11A gene; bottom: exon 2 with 
the binding recognition sites of the nucleases (zinc finger nuclease (Z), TALENs (T1, T2), and CRISPR/Cas9 guide sequence targets (g1–4)). 
The nucleases were delivered through electroporation. (b) Representative figure of CEL-1 surveyor assay used to measure the functional 
activity of the nucleases in the K562 cell line. The type of nuclease used is indicated; negative control (−) was not exposed to a nuclease and 
the positive control (+) was from a genomic DNA sample previously nuclease-treated and known to have insertions and deletions (indels). 
The nucleases were delivered at the following concentrations: ZFNs, 2 μg; T1–2, 2 μg; pX330.g1–4, 4 μg. (c) Assessment of expression and 
toxicity after electroporation of GFP expression plasmid and mRNA by flow cytometry (7-AAD) in CD34+ cells, 1 day post-electroporation, 
n = 3, *P < 0.05, **P < 0.01, ***P < 0.001. CD34+ cells were either suspended in electroporation buffer but not electroporated (untreated), 
electroporated without added nucleic acid (Mock (E)) or were electroporated with the indicated amounts of GFP plasmid (black bars) or GFP 
mRNA (gray bars). (d) Surveyor assay displaying CD34+ cells electroporated with RNA transcripts of ZFN (5 μg), TALENs (5 μg), and gR.1/
Cas9 (5 μg/5 μg). CRISPR, clustered regularly interspaced short palindromic repeat; TALEN, transcriptional activator-like effector nuclease; 
ZFN, zinc finger nuclease.
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induced in CD34+ cells after delivery of gRNA expression 
plasmid (pU6.g1) or RNA (gR.1) together with Cas9 mRNA 
was assessed by flow cytometry after 1 day. RNA delivery 
of gRNA was clearly associated with limited toxicity com-
pared to the gRNA expression plasmid (Supplementary 
Figure S3b,c).
To compare the DNA repair signatures created by these spe-
cific nucleases, we measured the frequencies of different sizes 
of indels at the target sites in K562 cells. After treating cells 
with the nucleases, the target region of the BCL11A locus was 
amplified by polymerase chain reaction (PCR) and the products 
TOPO cloned and sequenced. We found that the ZFNs were 
associated with 38% deletions (0–5 bp), 28% deletions (11–
20 bp) and also had 10% small insertions (0–5 bp), in contrast 
to the other nucleases that produced no insertions. The TALENs 
gave rise to larger lengths of deletions: T(1) 28% (6–10 bp) and 
23% (21–30 bp) deletions and T(2) 35% (6–10 bp) and 24% 
(21–30 bp) deletions. The four CRISPR/Cas9 combinations 
studied created mostly small deletions (0–5 bp), 69% (pX330.
g1), 50% (pX330.g2), 54% (pX330.g3), and 35% (pX330.g4), 
respectively, although the second CRISPR/Cas9 (pX330.g2) 
also yielded 25% deletions with the size range 11–20 bp and 
the fourth CRISPR/Cas9 (pX330.g4) gave rise to 42% dele-
tions with the range of 6–10 bp (Figure 3d). The overall muta-
tions resulting in a reading frameshift ranged between 90% and 
Table 1 Nuclease types and expression templates
Nuclease Form
ZFN (Z) mRNA (R)
TALENs (T1, T2) Plasmid (P)
mRNA (R)
Cas9 pX330 (CBh-Cas9-U6-gRNA plasmid (P))
mRNA (R)
gR.1–4 (gRNA (R))
pU6.g1–4 (U6-gRNA plasmid (P))
gDNA, guideDNA; TALEN, transcriptional activator-like effector nuclease; 
ZFN, zinc finger nuclease.
Figure 2 Delivery of CRISPR/Cas9 as plasmid, RNA or a combination of Cas9 mRNA and a plasmid expressing gRNA to CD34+ cells. 
(a) Electroporation of CRISPR/Cas9 plasmid (pX330.g1 at the concentrations: 1, 2, 5, 10 μg), or codelivery of pU6.g1 and Cas9 mRNA at the 
concentrations: pU6.g1(5 μg): Cas9 (5 μg) and pU6.g1(10 μg): Cas9(10 μg), or electroporation of gR.1 and Cas9 mRNA at the concentrations: 
gR.1(5 μg): Cas9(5 μg) and gR.1(10 μg): Cas9(10 μg) to CD34+ cells. Representative Surveyor assay showing efficiency of Cas9-mediated 
cleavage in CD34+ cells. (b) Efficiency of gRNA multiplexing mediated cleavage in CD34+ cells. gRNA multiplexing by expressing two to three 
copies of the same gRNA target sequence from one plasmid pU6.g2/Cas9 (one copy), pU6.g2.2/Cas9 (two copies), or pU6.g2.2.2/Cas9 (three 
copies) (n = 3–5). (c) Multiplexing mediated cleavage in CD34+ cells using different gRNAs; pU6.g1/Cas9 (one copy), pU6.g1.2/Cas9 (two 
copies), or pU6.g1.2.3/Cas9 (three copies) (n = 3–4). CRISPR, clustered regularly interspaced short palindromic repeat; gRNA, guideRNA.
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53%, where the pX330.g1 resulted in the highest percentage 
of reading frame shift (90%), followed by the pX330.g2 and the 
ZFNs (81%). The lowest reading frame shift was caused by the 
second TALEN pair (T2) (Figure 3e).
Assessment of nuclease specificity
To investigate the specificity of the nucleases, we began 
by analyzing the predicted off-target effects using the 
PROGNOS online tool for the ZFNs and TALENs24 (both 
obligate heterodimers) and the MIT-design web page for the 
CRISPRs. We designed primers and amplified the top five 
predicted regions with high homology to the on-target site 
from the bulk CD34+ population and analyzed cleavage by 
Surveyor assay. None of the predicted off-target sites for 
ZFNs and TALENs showed any cleavage activity. For the 
CRISPR/Cas9, only one potential off-target site was detected 
Figure 3 Determination of nuclease efficiencies and mutation signatures. (a) Electroporation of ZFNs and TALENs to CD34+ cells at 
various concentrations (n = 4). (b) Electroporation of gR.1 and Cas9 mRNA (n = 3). (c) Electroporation of pU6.g1 and Cas9 mRNA (n = 3–5). 
(d) (%) Indel frequencies and sizes induced by the respective nucleases (Z: n = 41, T(1): n = 45, T(2): n = 41, pX330.g1: n = 42, pX330.g2: 
n = 42), pX330.g3: n = 41, pX330.g4: n = 43. (e) (%) Mutations resulting in reading-frame shift. TALEN, transcriptional activator-like effector 
nuclease; ZFN, zinc finger nuclease.
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Table 2 Determination of nuclease specificity through genome-wide off-target site analysis; clustered integration sites (CLIS) within a 500 bp window resulting 
from NHEJ-mediated trapping of a GFP IDLV were analyzed for ZFNs and TALENs
Sample Chr
Location of 
CLIS
# of CLIS  
(Nuclease + GFP IDLV) Homology (%)
P value 
(homology) Nuclease dimer
Mismatches
Right Left
ZFN 2 60773423 60 100 0 R_6_L 0/18 0/18
21 37801559 3 64 0.808 R_5_L 7/18 6/18
X 39511878 6 58 0.998 L_5_R 6/18 9/18
16 10693191 3 58 0.998 R_14_L 6/18 9/18
16 62367206 2 58 0.998 L_15_R 9/18 6/18
2 143079893 2 56 0.999 L_20_R 7/18 8/18
X 150053186 2 56 0.999 L_4_R 8/18 8/18
T1 2 60773363 45 100 0 R_16_L 0/16 0/17
6 75985911 5 85 0 R_23_L 4/16 1/17
3 165333318 3 85 0 R_16_L 3/16 2/17
7 131418865 2 79 0.002 R_15_L 5/16 2/17
8 33301623 6 79 0.002 L_18_R 5/16 2/17
1 12304291 2 76 0.015 L_18_R 6/16 2/17
1 54169158 3 73 0.081 L_8_R 7/16 2/17
The top seven CLIS detected only with nuclease treatment are listed in descending order of homology to the intended nuclease target site. P values are calcu-
lated as an extreme value test of the CLIS maximal homology among a set of 20,000 randomly generated sites. For the ZFNs and TALEN, the nuclease dimer 
panel shows spacer size and left and right orientation of the nuclease monomers. Number of mismatches from on-target site for ZFNs and TALENs is shown. 
n = 6 biological replicates for nuclease + GFP IDLV and GFP IDLV only treatments. IS, integration site; L, left monomer; R, right monomer. IDLV, integrase-
deficient lentiviral vectors; NHEJ, nonhomologous end joining; TALEN, transcriptional activator-like effector nuclease; ZFN, zinc finger nuclease.
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when using pX330.g4, displaying 12% cleavage at the top 
predicted site (Supplementary Table S1).
We also investigated off-target cleavage with a less biased 
technique using NHEJ-mediated trapping of integrase-
deficient lentiviral vectors (IDLVs) to find unknown loci with 
recurrent DSBs.25 Sites where IDLVs were trapped were 
mapped using nonrestrictive linear amplification-mediated 
PCR followed by Illumina high-throughput sequencing.26 In 
the resulting sets of IDLV trapping sites, we looked for 500 bp 
windows containing more than one unique trapped IDLV, and 
then searched 1 kb of the hg19 human genome reference 
sequence centered on the center of mass of the IDLV integra-
tions for the sequence with maximal homology to the nucle-
ase recognition site. The ZFNs displayed high specificity for 
the BCL11A target locus, as all clustered integration sites 
(CLIS) identified had maximal homologies that were not sig-
nificantly higher than those from a set of 20,000 random clus-
ter sites generated in silico (all CLIS P > 0.05, Table 2). This 
is consistent with the identified CLIS being nearby trapping 
events by chance, rather than the result of off target nucle-
ase activity. The TALEN pairs yielded five off-target CLIS with 
maximal homologies significantly higher than those from 
randomly generated sites (P < 0.05, Table 2). Two of these 
significant off-target CLIS observed for the TALENs were 
confirmed by Surveyor nuclease assay, measuring the allelic 
disruption (Supplementary Figure S4a). pX330.g1 yielded 
three off-target CLIS with significant maximal homology, and 
one of these comprised 47 independent trapped IDLV on 
chromosome 11, a site that was not predicted as a potential 
off-target site by the MIT CRISPR Design Tool web resource 
(Table 3). The Surveyor assay revealed 29% allelic disruption 
at this off-target site, which is a similar level of cleavage as 
observed at the on-target site (Supplementary Figure S4b).
In vitro erythroid differentiation of BCL11A-edited CD34+ 
cells results in significantly increased HbF with the ZFNs
To assess the functional effects of the disruption created by 
the nucleases at the targeted BCL11A locus, we differentiated 
the nuclease-treated CD34+ cells using an established two-
phase erythroid differentiation culture model that generates 
enucleated erythroid cells27,28 (Figure 4a). Surveyor nuclease 
assay was performed on day 4 of the erythroid differentiation 
(Figure 4b), revealing indel rates of 25% for ZFNs, 11% for 
TALENs, 9% for pU6.g1/Cas9, and 5% for gR.1/Cas9.
To determine whether the erythrocyte differentiation 
capacity had been altered, surface markers (including: CD45, 
CD34, CD71 (transferrin receptor), CD235a (Glycophorin A)) 
and Draq5 staining to verify enucleation of red blood cells 
were used to monitor the cells appearance and contribution 
to the populations. Compared to unmodified controls from 
nontransfected samples, no differences were seen in the cul-
tures from nuclease-treated CD34+ cells (Figure 4c).
Erythroblasts were isolated and globin expression (HbA 
and HbF) was quantified by HPLC at day 12 and by flow 
cytometry at day 14. The ZFN nuclease-treated cells dis-
played a significant increase in HbF, resulting in a significant 
4.3-fold increase of HbF expression measured by HPLC and 
a significant 3.4-fold increase in γ-globin measured by flow 
cytometry (Figure 4d–f). The TALENs and CRISPR/Cas9 
were less effective and revealed no significant increase when 
measured by HPLC or flow cytometry.
Transplantation of modified CD34+ cells into immune-
deficient NSG mice
Finally, we transplanted nuclease-treated CD34+ cells in vivo 
intravenously into immune-deficient NSG mice. The mice 
received one million unmodified CD34+ cells (n = 6), or one 
million viable nuclease-treated CD34+ cells treated with ZFNs 
(n = 4), TALENs (n = 5), or CRISPR/Cas9 (pU6.g1/Cas9) 
(n = 4). Cell counts of nuclease-treated cells were assessed 
by trypan blue on the day after electroporation, showing more 
cell death induced by the ZFNs and CRISPR/Cas9 compared 
to the TALENs (Figure 5b), and cleavage efficiency was 
determined by Surveyor nuclease assay, after 4 days of in 
vitro culture (Figure 5a).
Two months after transplantation, we analyzed the cleav-
age percentage created by the nucleases in human cells 
in the peripheral blood (PB) from the transplanted mice 
 (Figure 5c). We detected cleavage only in the human cells 
that had been treated by ZFNs, ranging from 2% to 10%. No 
cleavage of the BCL11A gene was detected in the human 
cells treated by CRISPR/Cas9 and TALENs. Engraftment 
(%hCD45) and lineage analysis of human cells performed 
3 months post-transplantation in PB showed no significant 
differences between the ZFN-treated group compared to the 
untreated group. Strikingly, the mice transplanted with pU6.
g1/Cas9-treated cells showed no human engraftment in PB 
at 3 months (Figure 5d,e). Five months post-transplanta-
tion, measurement of engraftment levels as the percentage 
Table 3 Determination of nuclease specificity through genome-wide off-target site analysis; clustered integration sites (CLIS) within a 500 bp window resulting 
from NHEJ-mediated trapping of a GFP IDLV were analyzed for pX330.g1
Sample Chr
Location  
of CLIS
# of CLIS  
(Nuclease + GFP IDLV)
Homology 
(%)
P value  
(homology) Mismatches
pX330.g1 2 60773393 63 100 0 GAACCAGACCACGGCCCGTT GGG
11 107037788 47 90 0 GGACCAGACCACGGCCTGTT AGG
3 71514908 2 85 0 GTACCAGCCCATGGCCCGTT AGG
2 60772750 3 60 0.048 GAATCAGATGTAGGCAGGAT AGG
4 18760553 2 55 0.199 GAATGATACAATGGACTTTG GGG
4 101127131 2 55 0.199 GCAGGAAACTACGGAGCATG TGG
1 13941729 2 55 0.199 CACAGAGTCGGCAGCCCATT CGG
The top seven CLIS detected only with nuclease treatment are listed in descending order of homology to the intended nuclease target site. P values are 
calculated as an extreme value test of the CLIS maximal homology among a set of 20,000 randomly generated sites. Sequence mismatch for the pX330.g1 is 
shown. IDLV, integrase-deficient lentiviral vectors; NHEJ, nonhomologous end joining.
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Figure 4 In vitro erythroid differentiation of BCL11A-edited CD34+ cells. (a) Experimental design. Nuclease-treated CD34+ cells were 
subjected to in vitro erythroid differentiation. Samples were taken at the indicated days and stages for end-point testing. Basophilic erythroid 
(Baso-E), orthochromatic erythroid (Ortho-E). (b) Cleavage frequencies were assessed by the surveyor assay 4 days after electroporation of 
the ZFNs (Z), the TALENs (T1) nuclease, or the CRISPR/Cas9 using the gRNA expression plasmid (pU6.g1/Cas9) or RNA with Cas9 mRNA 
(gR.1/Cas9). Mean (±SD), *P < 0.05, **P < 0.01. (c) Flow cytometry measuring lineage markers at day 18–20 of erythroid differentiation. 
(d) On day 12 of the erythroid differentiation, the cells were lysed and HPLC was performed to determine proportions of HbA and HbF. 
(e) Quantification of the percentage of HbA and HbF determined by HPLC (n = 3). (f) Flow cytometric analysis of HbF and HbA in erythroid 
progenitors at day 14 of the erythroid differentiation (n = 3). CRISPR, clustered regularly interspaced short palindromic repeat; HPLC, high-
performance liquid chromatography; TALEN, transcriptional activator-like effector nuclease; ZFN, zinc finger nuclease.
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of hCD45+ cells in PB, bone marrow (BM), and spleen and 
lineage analyses of the human cells were conducted. Once 
again we observed failure of engraftment of the pU6.g1/Cas9-
treated CD34+ cells measured in all three organs  (Figure 5f).
The engraftment potential of the ZFN- and TALEN-treated 
CD34+ cells showed no significant difference compared to 
untreated CD34+ cells (Figure 5f), and the lineage analysis of 
these treatment groups showed no skewing in differentiation 
potential (Figure 5g). Surveyor assay of PB, BM, and spleen 
was performed 5 months post-transplantation and showed 
cleavage of the BCL11A gene in ZFN-treated CD34+ cells 
in BM (3.3–4.3% cleavage) and spleen (1.5–2.1% cleavage) 
(Figure 5h, Supplementary Figure S5a–c), but no cleav-
age was observed in PB. Neither of the other two nucleases 
(TALENs or CRISPR/Cas9) were able to induce cleavage of 
the BCL11A locus in CD34+ cells capable of engrafting in vivo 
(Figure 5h, Supplementary Figure S5a–c).
Discussion
Manipulation of the physiologic fetal-to-adult transition 
of hemoglobin expression via induction of knockdown of 
HbF repressors may ameliorate clinical manifestations of 
β-hemoglobinopathies. BCL11A, a direct regulator of HbF 
switching, was until recently considered a potential clinical 
target.18–23 Emerging evidence indicates that BCL11A knock-
down may lead to HSC impairment, as observed in competi-
tive transplantations,29 thus the erythroid-specific BCL11A 
enhancer might constitute a more suitable clinical target.24,30 
Nevertheless, the main focus of this study was not to deter-
mine the optimal clinical target, but to investigate and char-
acterize the technical aspects of targeted nucleases directed 
at the same locus, the BCL11A gene. Whereas mRNA 
delivery systems, i.e., ZFNs and TALENs, produce high fre-
quencies of nonhomologous chromosomal DNA indels in 
primary CD34+ cells, the CRISPR/Cas9 has only recently 
been reported to yield relatively efficient gene modification 
in human CD34+ cells.3 Previous studies have demonstrated 
high efficacy of ZFNs and TALENs after electroporation of in 
vitro transcribed mRNA to CD34+ cells.1,31,32 Data from Man-
dal et al.4 indicate that delivery of the CRISPR/Cas9 from the 
expression plasmid pX330 through electroporation to CD34+ 
cells requires selection by fluorescence-activated cell sort-
ing (FACS) to detect the nuclease-treated cells, due to low 
gene-editing efficiency in primary HSPCs. Using the same 
approach of plasmid-mediated CRISPR/Cas9 delivery and 
expression, but without selection, we were unable to detect 
any cleavage despite delivery of high concentrations of the 
plasmid, which confirms low efficiency associated with this 
strategy. Moreover, while the study by Mandal et al. did not 
address cytotoxicity induced by DNA delivery to HSPCs, we 
conducted such analyses and found that acute cytotoxicity 
induced cell death in ~50% of the cells. Due to the absence 
of cleavage, we investigated codelivery of plasmid gRNA and 
Cas9 mRNA, which proved to be a more efficient mode of 
delivery, as cleavage was detected, however, similar acute 
cytotoxicity was comparable to plasmid delivery alone. The 
limited pool of RNA pol III that expresses the gRNA in human 
cells may explain why we were not able to improve cleavage 
efficiency by multiplexing gRNA sequences to the BCL11A 
locus. Multiplexing of CRISPR/Cas9 might require further 
development of a system where the gRNA is expressed from 
RNA pol II.33,34 Delivery of gR.1/Cas9 mRNA resulted in ~5% 
allelic disruption, the lowest of all the nucleases. Nonetheless, 
RNA delivery of the CRISPR exhibited the lowest toxicity to 
CD34+ cells. A recent publication by Hendel et al.3 showed 
increased cleavage efficiency in CD34+ cells as well as T cells 
after chemically modifying the gRNA in three different ways 
(2´-O-methyl, 2´-O-methyl 3´´phosphorothioate, 2´-O-methyl 
3´thioPACE). Furthermore, Osborn et al.35 also investigated 
chemical modifications of the gRNA (2´-O-methyl) in Jurkat 
cells and human T cells and observed higher cleavage effi-
ciency after the chemical modification of the gRNA. While 
recognizing that efficacy and specificity may vary depending 
on target sequence, cell type, and delivery method, chemical 
alterations of the gRNA, protecting the sequence from deg-
radation, could be a promising strategy to increase cleavage 
efficiencies further in primary CD34+ cells.
In contrast to TALENs and CRISPRs, which only created 
deletions in this study, the mutation signature of the ZFNs 
was characterized by the presence of indels. The ZFNs and 
TALENs used in this study were obligate heterodimers, and 
thus required both proteins to heterodimerize in order to induce 
cleavage. Whereas the smaller spacer size of ZFNs (5–6 bp) 
might avert further cleavage after an indel has been created 
due to prevention of heterodimerization, the TALENs, with a 
larger spacer size (12–21 bp), may recleave the DNA despite 
being farther apart. It has been suggested that ZFNs induce 
more defined overhangs that get filled prior to NHEJ and this 
produces small insertions.36 The TALENs gave rise to larger 
deletions compared to ZFNs and CRISPRs, which most com-
monly induced small deletions. The different mutation signa-
tures were associated with differences in the frequency of 
reading-frame shifts. The nuclease pX330.g1 had the highest 
frequency of small deletions and gave rise to 90% frameshift 
mutations. The pX330.g2 and the ZFNs, both nucleases dis-
playing similar mutation signatures (large proportion of 0–5 bp 
and 11–20 bp), both gave rise to 81% frameshift mutations. 
Furthermore, the cleavage efficiencies differed among the 
nucleases; the studied ZFN pair had the highest cleavage 
efficiency, as confirmed by functional assessment in erythroid 
differentiation. At day 12 of differentiation, we observed a four-
fold increase in HbF expression as shown by HPLC and flow 
cytometry. The TALENs and CRISPR-modified populations 
resulted in a modest, nonsignificant increase in HbF expres-
sion, measured by HPLC.
ZFN and TALEN gene-edited CD34+ cells had the capacity 
to engraft in NSG mice, while retaining multi-lineage potential 
after 5 months. However, only ZFN gene-edited CD34+ cells 
exhibited gene modification after engraftment in vivo. Despite 
BCL11A being essential for lymphoid development,37,38 the 
observed knockdown of BCL11A in bulk BM cells (4%) 
 (Figure 5b) did not alter levels of B lymphoid cells in the ZFN-
treated group. This could be due to the low-to-absent gene 
modification levels of the sorted B cells from the ZFN-treated 
BM cells (0–3.7%) (Supplementary  Figure S6). Strikingly, 
when the plasmid-mediated CRISPR nuclease-treated 
CD34+ cells were transplanted into NSG mice, they failed 
to successfully engraft; the toxicity caused by plasmid deliv-
ery of the gRNA prevented engraftment of CRISPR-treated 
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HSPCs in the mice, indicating that such a delivery method is 
not appropriate for HSPCs.13,39
Previously, the specificity of target site recognition has 
been studied extensively in ZFN-based technology25 and 
CRISPR-based systems,40–42 but less so for TALEN-based 
approaches. Overall, evidence suggests that every tar-
geted locus is different and requires individual evaluation 
for off-target cleavage. While it is natural to commence with 
analyses of predicted off-targets to guide nuclease selec-
tion using web-tools, previous studies illustrate the need 
for unbiased genome-wide analyses to determine the true 
specificity.42 In this comparison study, we examined both in 
silico predicted off-targets and genome-wide analysis. The 
ZFN pair showed no significant off-target activity in either 
of these analyses. For the TALEN pair and the CRISPR, the 
less biased IDLV trapping based approach revealed signifi-
cant off-target cleavage, while the top five off-targets pre-
dicted in silico incurred no DSBs upon nuclease treatment. 
For the CRISPR, the IDLV trapping analysis found 47 inte-
gration sites at chromosome 11, a target site that was not 
predicted by the CRISPR Design Tool web-based software. 
Hence, global unbiased identification of DSBs is warranted 
to properly evaluate nuclease safety.
The ZFNs used for this study were identified via screening 
of a small panel of related designs for gene modification activ-
ity at the target shown in Figure 1a, as well as binding speci-
ficity as gauged via SELEX. In contrast, our TALENs and Cas9 
nucleases were generated via assembly and testing of single 
reagents, since at the time of these studies the standard engi-
neering principles for these platforms did not provide for alter-
native designs. More recently, variations to these platforms 
have been developed that afford greater design complexity, 
including alternative Cas9 sequences as well as an expanded 
repertoire of repeat variable biresidue (RVDs) for improved 
TALEN function.43–45 It is possible that the use of these plat-
form variations, coupled with a small-scale screening effort, 
Figure 5 Transplantation of nuclease-modified CD34+ cells into immune-deficient NSG mice. NSG mice were irradiated (250 cGy) 
and transplanted with 1 × 106 unmodified CD34+ cells Mock (n = 6) or 1 × 106 viable gene-modified CD34+ cells treated with ZFNs (Z) (n = 
4), TALENs (1) (n = 5), or CRISPR/Cas9 (pU6.g1/Cas9) (n = 4). (a) Surveyor assay determining the frequencies of cleavage in nuclease-
treated CD34+ cells after 4 days of in vitro culture. The remainder of the cells were transplanted into irradiated (250 cGy) NSG mice (1E6 
viable cells from each nuclease-treated group). (b) Cell counts 1 day post-electroporation (starting cell count number 9 × 106 cells). (c) Indel 
frequencies associated with the nucleases in peripheral blood (PB) 2 months after transplantation. (d) Engraftment analysis (%hCD45/
(%hCD45+%mCD45)) of human cells in PB, 3 months after transplantation. (e) Lineage analysis of human cells in PB, 3 months after 
transplantation. Myeloid cells (CD33), B-lymphocytes (CD19). (f) Engraftment analysis (%hCD45/(%hCD45+%mCD45)) of human cells in 
PB, bone marrow (BM), and spleen, 5 months after transplantation. (g) Lineage analysis of human cells in PB, BM, and spleen, 5 months 
after transplantation. Myeloid cells (CD33), B-lymphocytes (CD19), T-lymphocytes (CD3), and CD34+ cells. (h) Determination of (%) indels 
measured by the surveyor assay, in PB, BM, and spleen 5 months after transplantation. CRISPR, clustered regularly interspaced short 
palindromic repeat; TALEN, transcriptional activator-like effector nuclease; ZFN, zinc finger nuclease.
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could have yielded TALENs or CRISPR/Cas9 nucleases with 
improved properties.
In conclusion, our data contributes to an emerging appre-
ciation of the need to further investigate ways to optimize 
delivery of the CRISPR/Cas9 to CD34+ cells and shows 
that careful assessment of different gRNA sequences are 
required due to high variability of cleavage efficiencies in dif-
ferent loci and different types of cells.
Materials and methods
Cell lines and culture. K562 cells (ATCC, Manassas, VA) 
were cultured in RPMI 1640 (Cellgro, Manassas, VA) supple-
mented with Penicillin/Streptomycin/l-glutamine (100 units/
ml) (Gemini Bio-products, West Sacramento, CA) and 10% 
fetal bovine serum (FBS) (Gemini Bio-products). HEK293T 
cells (ATCC) were cultured in Dulbecco’s Modified Eagle’s 
Medium (Thermo Fisher, Grand Island, NY) supplemented 
with 1% Penicillin/Streptomycin/l-glutamine (100 units/ml) 
and 10% FBS. Adult human mobilized PB apheresis was pur-
chased from the Division of Experimental Hematology and 
Cancer Biology, Cincinnati Children’s Hospital Medical Center 
(Cincinnati, OH). CD34+ cells were isolated using the MACS 
CD34+ enrichment kit (Miltenyi Biotec, Auburn, CA) and the 
CliniMACS system (Miltenyi Biotec), resulting in a purity of 
96–98%. Human PB CD34+ cells were routinely cultured in 
medium containing X-VIVO 15 (Lonza, Walkersville, MD) 
supplemented with Penicillin/Streptomycin/l-glutamine and 
the cytokines recombinant human Stem Cell Factor (50 ng/μl), 
recombinant human thrombopoietin (TPO) (50 ng/μl), and 
Recombinant Human Flt3-Ligand (50 ng/μl) (Peprotech, 
Rocky Hill, NJ). The cells were cultured for 1–3 days prior to 
electroporation.
Transfection. Nucleofection of K562 cells was performed using 
a Nucleofector 4D (Lonza). 2 × 105 K562 cells (alternatively 
1 × 106) were centrifuged (90g) for 15 minutes and cell pellets 
resuspended in 100 μl of SF solution (Lonza) together with the 
DNA or RNA encoding the nuclease. The cells were thereaf-
ter nucleofected using the recommended program FF120 and 
transferred into a 24-well (alternatively a 6-well) tissue culture 
plate (Corning, Corning, MA) containing culture medium (RPMI 
1640) supplemented with Penicillin/Streptomycin/l-glutamine 
(100 units/ml) and 10% FBS and moved into the 37 °C incuba-
tor (NuAire, Plymouth, MN). Electroporation of PB CD34+ cells 
was performed using the ECM 830 Electroporation System 
(Harvard Apparatus, Holliston, MA). 2 × 105 cells were centri-
fuged (90g) for 15 minutes and cell pellets resuspended in 100 
μl of BTX solution (Harvard Apparatus) together with the DNA 
or mRNA encoding the nuclease. The cells were thereafter 
electroporated using 250 V, 5 ms, 1 pulse, and transferred into 
a 24-well tissue culture plate (Corning) containing X-VIVO 15 
(Lonza) supplemented with Penicillin/Streptomycin/l-glutamine 
and the cytokines recombinant human SCF (50 ng/μl), recom-
binant human TPO (50 ng/μl), and Recombinant Human Flt3-
Ligand (50 ng/μl) (Peprotech).
Surveyor nuclease assay. Genomic DNA was isolated using 
the PureLink Genomic DNA mini kit (Life Technologies). To 
determine allelic disruption, a 410 bp region surrounding the 
binding sites of the nucleases in BCL11A was amplified using 
PCR (Applied Biosystems/Life Technologies, Carlsbad, CA). 
The PCR reaction was performed using Accuprime Taq HiFi 
(Life Technologies) and the forward primer (5´-GGTGGGATGG 
CATGGGGTTGAGA-3´) and reverse primer (5´-CAGGTCA 
CGCCAGAGGATGACG-3´) (94 °C for 2 minutes, then 30 
cycles of 94 °C for 30 seconds, 62 °C for 30 seconds, and 68 °C 
for 1 minute, 68 °C for 5 minutes and finally 4 °C). PCR prod-
ucts were diluted 1:2 in 1× Accuprime buffer and thereafter 
denatured and reannealed (94 °C for 10 minutes, 85 °C (cool-
ing at −2 °C per second) and cooling to 25 °C (−0.1 °C per 
second)). Finally, the PCR product was digested with 1 μl of 
Surveyor Nuclease (Transgenomic, Omaha, NE) at 42 °C for 
15 minutes and run on an 8% TBE polyacrylamide gel (Life 
Technologies) at 120 V. The gel was stained with Gel Green 
(Phenix Research Products, Candler, NC) (1:10) in 1× TBE for 
20 minutes and imaged on a Kodak Molecular Imaging Station 
(Kodak, Rochester, NY). Allelic disruption was determined by 
densitometry using the formula: % Allelic disruption = 100 × 
(1−√(intensity of the uncut band/total intensity of cut and uncut 
bands)).
In vitro erythroid differentiation. The erythroid differentiation 
protocol is adapted from Giarratana et al.28 as described in 
Romero et al.27 The PB CD34+ cells were prestimulated for 
3 days in X-VIVO 15 (Lonza) supplemented with Penicillin/
Streptomycin/l-glutamine and the cytokines recombinant 
human Stem Cell Factor (50 ng/μl), recombinant human TPO 
(50 ng/μl), and Recombinant Human Flt3-Ligand (50 ng/μl) 
(Peprotech) prior to electroporation and thereafter transferred 
into erythroid medium (Iscove’s Modified Dulbecco’s Medium 
(Life Technologies) (1× glutamine, penicillin, and streptomy-
cin)) supplemented with 10% bovine serum albumin, 40 μg/
ml inositol, 10 μg/ml folic acid, 1.6 μmol/l monothioglycerol, 
120 μg/ml transferrin, and 10 μg/ml insulin (Sigma-Aldrich, 
St. Louis, MO). The cells were cultured with 10−6 mol/l hydro-
cortisone (Sigma-Aldrich), 100 ng/ml hSCF, 5 ng/ml hIL-3, 
and 3 IU/ml erythropoietin (Epo) (Janssen Pharmaceuticals, 
Titusville, NJ) for the first 6 days. The following 3 days, the 
cells were cocultured with stromal cells (MS-5, murine stro-
mal cell line46) and only Epo (3 IU/ml) was added to the ery-
throid medium. From day 11 to day 21, all the cytokines were 
removed from the basic erythroid medium. HPLC of hemo-
globin tetramers in erythroblasts at day 12 of culture was per-
formed as described.31
Chromosomal indel analysis. Genomic DNA was collected 
from K562 cells electroporated with the respective nucleases 
after 3 days, and PCR was performed to amplify the region sur-
rounding the cut site in BCL11A (Fwd 5´-GGTGGGATGGCAT 
GGGGTTGAGA-3´ and Rev 5´-CAGGTCACGCCAGAGGA 
TGACG-3´). The PCR product was cloned into a Topo TA clon-
ing vector (TOPO TA cloning kit from Invitrogen, Carlsbad, CA) 
and transformed into Top10 cells. The colonies were screened 
using X-gal to enrich for clones with the PCR product. Plas-
mid isolation was performed using the Purelink Quick Plasmid 
Miniprep Kit (Invitrogen) and sent for sequencing analysis to 
Laragen (Culver City, CA). A plasmid Editor (Ape) by M. Wayne 
Davis was used for sequence alignments.
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Predicted and genome-wide off-target analysis. The predicted 
off-target sequences for the four CRISPR/Cas9 were assessed 
using the Zhang CRISPR Design online Tool.40 The off-target 
sequences for TALENs and ZFNs were assessed using the 
Bao lab online PROGNOS (Predicted Report of Genome-wide 
Nuclease Off-target Sites) tool.24 Primers were designed for 
regions with the highest likelihood of having off-target cleavage 
for each nuclease tested, and Cel-1 assays were performed of 
these sites on genomic DNA previously isolated from electro-
poration experiments in K562 cells and CD34+ PBSCs.
The IDLV trapping protocol was adapted from Gabriel et al.25 
A titration of the nucleases with an IDLV expressing GFP (1.55E 
+ 09 TU/ml) was performed at an multiplicity of infection (MOI) 
of 3, 30, and 100 to determine the optimal amount of IDLV to be 
trapped by NHEJ at nuclease-induced DSB with minimal back-
ground capture in control samples. Six independent replicates of 
K562 (2 × 105) cells were electroporated with optimized amount 
of nuclease and GFP IDLV was added at an MOI of 30 to the 
post-electroporation recovery medium: RPMI 1640 (Cellgro, 
Tewksbury, MA) supplemented with 1% Penicillin/Streptomycin/l-
glutamine (100 units/ml) (Gemini Bio-products) and 10% FBS 
(Gemini Bio-products). Six control replicates were performed with 
only IDLV (MOI 30) added to determine the background capture 
rate and to distinguish between DSBs caused by nuclease activ-
ity and DSBs occurring at fragile sites in the genome. Five days 
post-electroporation, we confirmed that cleavage occurred at 
the target sites in the nuclease + IDLV samples by the Surveyor 
nuclease assay, but not in the control samples that received no 
nuclease. The cells were subsequently cultured for 7 weeks. 
Each week, the percentage and mean fluorescent intensity of 
GFP-positive cells were analyzed by flow cytometry. Additionally, 
the vector copies per cell (VC/cell) were determined by digital 
PCR to ensure elimination of nontrapped GFP IDLV. Genomic 
DNA for digital PCR was isolated using the PureLink Genomic 
DNA Mini Kit (Invitrogen). The average VC/cell was determined 
by duplex droplet digital PCR with normalization to the autoso-
mal locus uc378 to calculate the average VC/cell. After 50 days, 
nontrapped IDLV was sufficiently diluted out of the sample and 
GFP-positive cells were sorted by FACS for genomic DNA extrac-
tion. A biotinylated primer designed to the U5 region of the IDLV 
LTR was used to selectively amplify 3ʹ vector–genome junctions 
by nonrestrictive linear amplification-mediated PCR.26,47 Librar-
ies were then prepared for high-throughput Illumina paired-end 
100 sequencing. Vector integration sites were analyzed using a 
custom Python wrapper for the Bowtie2 aligner, and CLIS were 
defined as two or more integration sites in a sliding 500 bp win-
dow. Any CLIS found in nuclease + IDLV samples that did not 
overlap CLIS in IDLV only control samples were considered to 
be potential off-target sites for further analysis.
Mice. NOD/SCID IL2R gamma−/− (NSG) mice obtained from 
the Jackson Laboratory (Bar Harbor, ME) were maintained by 
the UCLA Department of Laboratory Animal Medicine under 
protocols reviewed and approved by the UCLA Chancellor’s 
Animal Research Committee (ARC# 2008–167).
1 × 106 CD34+ cells were electroporated with the respective 
nucleases, as previously described, and transplanted intra-
venously by tail vein injection, 1-day post-electroporation, 
into irradiated (250 cGy) NSG recipient mice. Engraftment 
and lineage analyses of PB, BM, and spleen were performed. 
Antibodies directed against hCD45-V450 and mCD45-FITC 
were used for engraftment analysis and CD19-PeCy7, CD3-
PerCP, CD33-PE, and CD34-APC were used for lineage anal-
ysis. Genomic DNA was prepared as previously described to 
assess the BCL11A disruption.
Statistical analysis. For measurements related to efficiency and 
toxicity, descriptive statistics such as mean, standard deviation, 
count, and percentage were summarized and presented in fig-
ures and tables. Statistical significance of comparison between 
two experimental arms was determined by two-sided unpaired 
t-test. P < 0.05 was considered statistically significant. Statisti-
cal analyses were carried out using GraphPad Prism version 
6.00 for Mac OS X (GraphPad Software, San Diego, CA, www.
graphpad.com). In the bioinformatic analysis of nuclease speci-
ficity assessment, an extreme value test was used for testing 
maximal homology. Specifically, a set of 20,000 random sites 
was generated in silico and 1 kb windows for these sites were 
searched for maximal homologies to the recognition site of the 
nuclease being considered. P values were calculated by deter-
mining the percentile within the 20,000 maximal homologies 
of random sites at which the CLIS maximal homology fell. For 
example, if a CLIS maximal homology would rank 200th in the 
list of random site homologies sorted in descending order, it 
would receive a P value of 0.01 (200/20,000).
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